All articles by Phillip Broadwith – Page 15
-
Business
Lanxess to cut 1000 jobs over two years
Agrium also cutting 500 positions and divesting underperforming business segments
-
Business
Chinese buyer resurrects US Boehringer plant
UniTao will take over manufacturing site scheduled for closure, saving over 200 jobs
-
Business
EU warns DuPont and Honeywell over green refrigerants
Commission thinks cooperation may have been anti-competitive
-
Business
Judge slashes fines in drug safety case
Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million
-
Business
Platform to expand in agrochemicals by buying Arysta
Business will be integrated with previous acquisitions for a broad crop protection portfolio
-
BusinessCHF3bn redevelopment for Roche’s Basel site
New buildings will move employees out of rented office space
-
Business
Amgen stacks up additional job cuts
Up to 1100 more staff face redundancy in ongoing restructuring plan
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
Business
Endo outbids QLT for Auxilium merger
Biotech backs out of Canadian deal in favour of increased $2.6bn bid from Endo
-
Business
EMA finalises trial transparency rules
Researcher access reinstated, but company redaction rights may cause issues
-
Business
Actavis boosts antibiotics with Durata buyout
$820 million deal gives Actavis control of newly-approved intravenous antibiotic
-
Business
Becton Dickinson to buy CareFusion for $12bn
Medical devices merger continues consolidation trend
-
Business
J&J to buy antiviral specialist Alios
$1.75 billion deal brings Phase II compounds for hepatitis C and respiratory syncytial virus
-
Business
Dow’s $1bn price-fixing fine upheld
Firm loses its appeal against damages for fixing polyurethane prices
-
Business
Mitsubishi to buy Japanese gases specialist
Taiyo Nippon Sanso acquisition continues consolidation in Japan’s chemical industry
-
Business
Lumara splits and sells to AMAG and Perrigo
Lumara has just emerged from bankruptcy and brings a drug for suppressing pre-term birth, plus other women’s health products
-
Business
India backs off drug pricing controls
Current price caps will stand, but rules on how new caps can be imposed are being tightened
-
Business
Review says cheaper drug is safe for eye disease
Cochrane collaboration says side effects of expensive Lucentis and off-label Avastin are similar
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
BusinessFreeing a world of fixers
Company profile: Sugru mouldable silicone rubber lets you mend what’s broken and hack stuff better